Review: Lasmiditan Drug Discovery for Acute Migraine Treatment
Background: Lasmiditan is a compound developed by Eli Lilly and Company named REYVOW®. Lasmiditan is a highly selective 5-hydroxytryptamine (5-HT1F) receptor agonist, indicated for the treatment of acute migraine with or without aura.
Objective: This review article aimed to discuss the review of the drug discovery of lasmiditan.
Data Source: The author made this review article using the literature study method that is relevant to the purpose of the review. Sources of information from national journals and international journals are accessed through online sites such as Google Scholar, Research Gate, Science Direct, Springer Link, and NCBI. The keywords used to search for journals are Lasmiditan, Migraine, Reyvow®.
Conclusion: Lasmiditan is a highly selective 5-hydroxytryptamine (5-HT1F) receptor agonist, lasmiditan is the only drug approved for the treatment of acute migraine with or without aura whose mechanism of action is specific to the 5-HT1F receptor which has no vasoconstrictive effect.
2. Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1211–1259.
3. World Health Organization. (2011). Atlas of headache disorders and resources in the world 2011. Geneva: World Health Organisation. Nutr Today. 1986; 20(1):8–9.
4. Hou M, Xing H, Li C, Wang X, Deng D, Li J, et al. Short-term efficacy and safety of lasmiditan, a novel 5-HT1Freceptor agonist, for the acute treatment of migraine: A systematic review and meta-analysis. J Headache Pain. 2020; 21(1):1–12.
5. Becker WJ. Acute migraine treatment in adults. Headache: The Journal of Head and Face Pain, 55(6), 778-793. 2015; 778–93.
6. Mecklenburg J, Raffaelli B, Neeb L, Sanchez del Rio M, Reuter U. The potential of lasmiditan in migraine. Ther Adv Neurol Disord. 2020;13:1–11.
7. Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010; 30(10):1159–1169.
8. Pilgrim AJ, Reuter U, Diener HC. Lasmiditan. Nov Approaches Migraine Treat. 2013; 37–45.
9. Lamb YN. Lasmiditan : First Approval. Drugs [Internet]. 2019;(0123456789). Available from: https://doi.org/10.1007/s40265-019-01225-7
10. Mohammed, A. M., Srinivas, N. S., Mohammed, S. U. R., & Ahmed M. Drug Information of Lasmiditan and Its Effectiveness for Maigraine. Asian Journal of Pharmaceutical Research and Development, 8(5), 140-142. Asian J Pharm Res Dev. 2020; 8(6):77–80.
11. Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: A review and potential role in clinical practice. J Pain Res. 2018; 11:2221–7.
12. Curto M, Cipolla F, Cisale GY, Capi M, Spuntarelli V, Guglielmetti M, et al. Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother [Internet]. 2020; 21(2):147–153. Available from: https://doi.org/10.1080/14656566.2019.1694004
13. Lilly E. REYVOW (lasmiditan) tablets, for oral use [controlled substance schedule pending]: US prescribing information. 2019.
14. Labastida-ram A, Johnson KW, Danser AHJ, Villal CM. Release in the Rodent Trigeminovascular System. 2020; 00(00):1092–9.
15. Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, van den Bogaerdt A, Bogers AJJC, Zanelli E, et al. Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol. 2019; 176(24):4681–4695.
16. Rizzoli PB. Emerging therapeutic options for acute migraine: Focus on the potential of lasmiditan. Neuropsychiatric Disease and Treatment. 2014;10:547–51.
17. Neeb L, Reuter U. Lasmiditan for acute migraine treatment. 2013; 631–638.
18. Rau JC, Navratilova E, Oyarzo J, Johnson KW, Aurora SK, Schwedt TJ, et al. Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia. 2020; 40(9):903–912.
19. Tsai M, Case M, Ardayfio P, Hochstetler H, Wilbraham D. Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol. Clin Pharmacol Drug Dev. 2020; 9(5):629–638.
20. Wilbraham D, Berg PH, Tsai M, Liffick E, Loo LS, Doty EG, et al. Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study. J Clin Pharmacol. 2020; 60(4):495–504.
21. Pearlman EM, Wilbraham D, Dennehy EB, Berg PH, Tsai M, Doty EG, et al. Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol. 2020; 35(5):1–11.
22. Ferrari MD, Färkkilä M, Reuter U, Pilgrim A, Davis C, Krauss M, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - A randomised proof-of-concept trial. Cephalalgia. 2010; 30(10):1170–1178.
23. Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen J, Harner N, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT 1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol [Internet]. 2012; 11(5):405–413. Available from: http://dx.doi.org/10.1016/S1474-4422(12)70047-9
24. Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018; 91(24):E2222–32.
25. Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019; 142(7):1894–1904.
26. Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, et al. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies. Headache. 2019; 59(10):1788–1801.
27. Loo LS, Plato BM, Turner IM, Case MG, Raskin J, Dowsett SA, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine : findings from the phase 3 trials ( SAMURAI and SPARTAN ). 2019;1–8.
28. Krege JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J, et al. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN. Cephalalgia. 2019; 39(8):957–966.
29. Tepper SJ, Krege JH, Lombard L, Asafu-Adjei JK, Dowsett SA, Raskin J, et al. Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials. Headache. 2019; 59(7):1052–1062.
30. Shapiro RE, Hochstetler HM, Dennehy EB, Khanna R, Doty EG, Berg PH, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: Post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019; 20(1).
31. Smith T, Krege JH, Rathmann SS, Dowsett SA, Hake A, Nery ESM, et al. Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies. Neurol Ther [Internet]. 2020; 9(2):459–471. Available from: https://doi.org/10.1007/s40120-020-00185-5
32. Tepper SJ, Vasudeva R, Krege JH, Rathmann SS, Doty E, Vargas BB, et al. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks. Headache. 2020; 60(8):1601–1615.
33. Knievel K, Buchanan AS, Lombard L, Baygani S, Raskin J, Krege JH, et al. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans. Cephalalgia. 2020; 40(1):19–27.
34. Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019; 39(11):1343–1357.
35. Lipton RB, Lombard L, Ruff DD, Krege JH, Loo LS, Buchanan A, et al. Trajectory of migraine-related disability following long-Term treatment with lasmiditan: Results of the GLADIATOR Study. J Headache Pain. 2020; 21(1).
36. Reuter U, Israel H, Neeb L. The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord. 2015; 8(1):46–54.
37. Tsai M, Nery ESM, Kerr L, Khanna R, Komori M, Dennehy EB, et al. Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine. Clin Pharmacokinet [Internet]. 2021; 60(6):819–828. Available from: https://doi.org/10.1007/s40262-020-00966-z
38. Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Hake AM, et al. Lasmiditan mechanism of action - Review of a selective 5-HT1Fagonist. J Headache Pain. 2020; 21(1):1–13.
39. Brashier D, Maggo S, Gill S, Angrish P, Singh A, Rawat D. Lasmiditan: new drug for acute migraine. 2019; 8(2):372–6.
40. Macone AE, Perloff MD. Lasmiditan: Its Development and Potential Use. Clin Pharmacol Drug Dev. 2020; 9(3):292–296.
41. Carniaux, Jean-Francois and JC. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists. 2014 U.S. Patent No. 8,697, 876.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).